Joined Apr 23 2013
Zhou laboratory published the first ion-trap mass spectrometry based glycosphingolipidomics analysis in the field of T cell epitope discovery (R01 project), and the first computer-predicted glycopeptide epitope library for cancer vaccines. These studies have led to licensing of a cancer-specific monoclonal antibody to BioLegend, San Diego, which is among few monoclonal antibodies showing preferred binding to a known glycosylated sequence, as well as start up of a biotechnology company, Nanocruise pharmaceuticals. Zhou and colleagues' discoveries have been cited in textbooks of glycobiology and immunology, including Handbook of Glycosyltransferases and Related Genes, Essentials of Glycobiology, and Fundamental Immunology. Zhou has received the Cancer Research Institute Irvington Postdoctoral Fellowship Award, People's Republic of China Ministry of Education's Chunhui Prize for Innovation and Entrepreneurship, and PRC's 1000Plan Professorship for Young Talents.